-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, N90/iUuOmuxDkNyFmQBfZ/GnSl/ZJCD06Pn1lH1vWJbQ+/gPDyVWyTdbF1iLsCCd ZdaRZvPXB/HWzLDLOnEdgg== 0000950103-06-001076.txt : 20060412 0000950103-06-001076.hdr.sgml : 20060412 20060412131324 ACCESSION NUMBER: 0000950103-06-001076 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20060412 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060412 DATE AS OF CHANGE: 20060412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 06755383 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp02421_8k.htm
 
 
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
 
Washington, D.C. 20549 
 
FORM 8-K
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  April 12, 2006

Shire plc

(Exact name of registrant as specified in its charter)
 
England and Wales

(State or other jurisdiction of incorporation)

0-29630   98-0484822
(Commission File Number)   (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England

(Address of principal executive offices) (Zip code)
   
Registrant’s telephone number, including area code 44 1256 894 000

 

(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01. Other Events

     Shire plc has issued the press release attached as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

                 (c) Exhibits. The following exhibit is filed herewith:

99.01 Press Release dated April 12, 2006






SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



SHIRE PLC
     
By:  /s/ A C Russell
 
  Name: Angus Russell
  Title: Chief Financial Officer

Dated: April 12, 2006






EXHIBIT INDEX

 

Number   Description
99.01   Press Release dated April 12, 2006





EX-99.1 2 dp02421_ex9901.htm
    EXHIBIT 99.01
  Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
     
  Press Release  
     

12 April 2006

Shire plc (the “Company”)

The Company announces that, on 11 April 2006, it was notified, pursuant to sections 198 to 202 of the Companies Act 1985, that, on 11 April 2006, Prudential Assurance Company Limited was interested in 15,063,989 ordinary shares of £0.05 each in the capital of the Company. This holding represents 3.02 per cent of the issued ordinary share capital of the Company.

T May
Company Secretary

For further information please contact:

Investor Relations Cléa Rosenfeld (Rest of the World) +44 1256 894 160
  Brian Piper (North America) +1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies - all being areas in which Shire has a commercial presence. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. Shire’s strategy is to develop and market products for specialty physicians. Shire’s in-licensing and merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com

 

Registered in England 2883758 Registered Office as above

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``T)"@L*"`T+"@L.#@T/$R`5$Q(2 M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__ MVP!#`0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/ M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P``1"``Z`,@#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#TZBBB@`HH MK'\4:W'HFE22AT^TN-L"'N?7'H.M-)R=D!-JNO:9I`Q>W2K)C(C7YG/X"N"-0D MA!A-O98!QYA\R4_[Q'`_X#^M=7LJ3V+DGQ&M@GR:;,7]&D`'Y\U>LM M<\07\'VJTTRPFA[JEV"WTST!^M<1K7A?4]&B,]RL;&V0,],@\BJ_A_5 MYM&U2*YCE?\)58PZ?]IOXYK5TF\B2%D+, MCXSCCMCG-/TWQ5I.J7J6=I)(TS@D!HR!P,]:P?B%!&FD)<1MN-S=JY(]!&0/ MT%<_X#_Y&RU_W9/_`$$UFJ47!R*YG>QZS1117*61W$R6]O+/*2$B0NQ`SP!D MUSW_``G>@_\`/:;_`+\FMS4H7N=,NK>+&^6%T7)P,E2!7FG_``@6N_W;7_O[ M_P#6K:E&$E[S)DWT/48)DN+>.>,DI(H=<^A&13ZKZ?"]OIUM!)C?%$B-CID` M"K%9,H****0!1110`4444`%%%%`!1110`445S7B#Q#+#=II&B*)M3E.">JQ# MW]_Y=ZJ,7)V0F[$OB;Q`^F".TTY$N-2F8!8>25!SS@5@ZK;3:'IT>N:@GV[5 M9V"YN,%+.+J=RVKQ:E=.T\R2K(=YZX.<>PKV#3=7L-4B#V M5U%(V,E`WS+]0>:\KUSPSJ.CS-OA::W_`(9HU)&/?T-8ZL58,I((Z$&NJ=.- M5)IF:;CN>Y7]I'?V,]I-]R9"A/IGO^%#;B*T\10W%PX2*..1F9N@&PUUOQ,_Y`EK_U\#_T M%J\_TRRDU'4;>SBX:9PN?0=S^`YK6EK2U)E\1N:GXXUB\D86TBVD6>%C&6Q[ ML?Z8J"S\9:[:L,W?GKGE9D#9_'K^M=O%X%T%(0DD,LK8Y=I6!_3`K@/%&D)H MFLO:1.S1%!)&6ZX/K^(-%.5*?NI`U):GI=GK)O\`PK)JD(5)5@=BHY".H/'Z M5P?_``G6N_\`/6'_`+]"K?@JYD.A:]:$YC6W:11Z$JP/\A7'4J=**N M!6!XT^]I'_8.C_K6%8V]S?7$=C:AF>9QA`>">>3]`3^M.-*+AL',[FS?>,]< MNW)2Z%LF>$A4#'XGFN[37!8>#[74[V023/;H0&.#*Y7..!63;_#JR$0^TWUP MTF.3&%49_$&N.\07AFO%LXY2]K8+]G@SW"\%OJ6G4LH]!W<=R_>^-]; MNB?*F2V0_P`,2#/YG)JO;>+]>MFR+]I!W650P/Z9KH/"'A"SO--34-41I/-R M8XMQ4!<]3CDYK3UOP3IL]E*^FV_D72*2@1CM<^A!H$_$JZY` M\=QY45Y&>8T)^9>/F`/N<=ZZ*O#;"]GTZ^BN[=BLL39^OJ#['I7MEG)-)U6[^RV5P7EVEMIC9>!]1 M4]]HNEZ@"+NQ@D)_BVX;\QS7C^DZC-I6HPWMO@O&>5/1AW!KTFP\!,9)[F=J_P_MFB:329GCD`)\J0[E;V!ZC]:\[(* MDJPP1P0:]0U/QYI5M$18E[N4C@!2J@^Y/]*\Q=FED+'EG.3[DUO0Y[>\1*W0 MZK5KQKSX>Z8SDEXKDQ$GO@-C],54\!C_`(JRU]ED_P#0#6EXAT]],\!Z9;S* M5E\_?(#V)#''X=*SO`?_`"-EK_NO_P"@FDK>SE;S']H]9KS/XE_\AZW_`.O4 M?^A-7IE>9_$O_D/6W_7J/_0FKGP_QE3V(_!7_'AKW_7D?Y-7*5U?@K_CPU__ M`*\C_)JY2NR/Q2,WLCI?&GWM(_[!T?\`6K/PVB5]?FD/6.W./Q8"JWC3[VD? M]@Z/^M7?AG_R&;K_`*]__9A6;_@L:^(]&ESY+[>NTXKP89QSUKWRO&O%&EOI M.N7$)0B%V,D)[%3_`(=/PK+"M7:*F);Z3KTUO'+;6MXT+*"A7."/:I?[%\2? M\^=__P"/5TW@KQ59P:H>%H9[?PY90W4;1RHA#* MPP1R*V+2OMC3RR3R>!UKTF`2+!&)V5Y0HWLHP">^!6=> M4K)2'!+H/HHHKF+"BBB@#E]?\&V^J7C7UM<1DG/DR_=_!NH_&N>E\%^((VP+(. M/595_P`:];HK:.(FB7!'DT/@C7Y2-UJD0]7E7^A-=;H'@>UTZ:.ZO93MZ=#;V1B#I-O/F,0,8(]#ZUB>%_". MJ:5KL-[=-;&)`P.QR3RI'I[UW=%2JLE'E6P^57N%<;XQ\,:CK>J0W-DT`C2$ M(?,<@YW,?0^M=E14PFX.Z!JYQ7ASPMJ6F6NJ1W+6Y:ZMS%'L]8?\` MP@&M_P!^S_[^G_XFO4:*T5>:;8N5'#^(_">IZFU@;9KM`4DBV#RW).<@^@]*["BDZTN7E#E5[A6;KFB6>N6@@N@59 M3F.5?O(?\/:M*BLTVG=%'E]]X!U>"5A:&&YCS\I#!&_$'_&J\7@C7Y&`:VCC M'J\JX_0FO6**W6)G8CD1S7AGPC;Z*XNIY//O,8#8PJ9ZX']:Z6BBL92
-----END PRIVACY-ENHANCED MESSAGE-----